A Precision Medicine Approach to Treating Alzheimer’s Disease Using Rosiglitazone Therapy: A Biomarker Analysis of the REFLECT Trials is a dataset published in Journal of Alzheimer s Disease (2021). On theSindex it has a DataRank of 0.728, placing it in the top 27.6% of the data-sharing corpus. It has been cited 21 times, with 13 citing works in its 1-hop citation network.
Ranks in the top 28% for downstream scientific impact
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.464
From this paper's citation signal
Citation Network Contribution
0.264
From 12 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 13 citers.
NIA NIH HHS
Grant: P30 AG062429
NIA NIH HHS
Grant: R01 AG018440
NIA NIH HHS
Grant: R01 AG051848
National Institutes of Health
Grant: 5P30AG062429-03
UCSD Alzheimer's Disease Research Centers P30
National Institutes of Health
Grant: 5R01AG051848-02
A Proinflammatory Endophenotype to Predict NSAID Treatment Response Alzheimer's Disease Clinical Trials
National Institutes of Health
Grant: 5R01AG018440-03
B-Synuclein as a Treatment for Lewy Body Disease
FWCI
2.03
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals